Yangyi Lin

Dr. Yangyi Lin


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 May 2026 in Biomedicines
Verified
Journal Article
Open access
PDF file
XWXinyun Wang
Xinyun Wang
YLYangyi Lin
Yangyi Lin
WLWei Liu
Wei Liu
YWYufeng Wu
Yufeng Wu
BYBoshen Yang
Boshen Yang
XJXian Jin
Xian Jin
Background: Emerging evidence has established ferroptosis as a vital factor in the pathogenesis of cardiovascular diseases, especially in septic cardiomyopathy (SCM). Meanwhile, ondansetron (OND), a well-established 5-HT3 receptor antagonist, has gained increasing attention for its pleiotropic effects. However, its potential to modulate ferroptosis in the cardiovascular field remains unexplored. This study aims to fill this gap by exploring the potential of OND as an innovative therapeutic intervention for SCM. Methods: This study utilized both in vitro and in vivo models of septic cardiomyopathy (SCM), which was induced by lipopolysaccharide (LPS) stimulation in neonatal rat cardiomyocytes (NRCMs) and C57BL/6 mice. Through RNA sequencing, as well as molecular and functional assessments—including echocardiography and ferroptosis-related measurements—we revealed the anti-ferroptotic effect of ondansetron (OND). Mechanistically, ATF3 was identified as a pivotal regulator, with its overexpression via AAV9 in vivo and ADV in vitro confirming its role in OND-induced cardioprotection. Results: Ondansetron (OND) showed potent anti-ferroptotic effects in both cellular and murine models of septic cardiomyopathy (SCM). Treatment with OND not only improved cardiac performance but also reduced ferroptotic markers, mitigated lipid peroxidation and iron overload, and bolstered antioxidant defense. Notably, OND administration attenuated oxidative and endoplasmic reticulum (ER) stress while restoring mitochondrial integrity. Mechanistically, the anti-ferroptotic activity of OND was mediated through the HTR3A/ATF3 axis: ATF3 overexpression negated OND’s protective effects, while HTR3A antagonism with VUF10166 recapitulated its benefits. Conversely, HTR3A agonism with PBG attenuated ferroptosis resistance, further implicating this pathway as central to OND’s mechanism. Conclusions: This study demonstrated a novel pharmacological role for ondansetron (OND) in attenuating ferroptosis in septic cardiomyopathy (SCM) via the HTR3A/ATF3 signaling pathway. This finding delineates a novel therapeutic avenue and supports the repurposing of OND beyond its traditional antiemetic use to cardiovascular applications.

1 November 2022 in JAMA Internal Medicine
Verified
Journal Article
Closed access
PDF file
SWShiwang Wang
Shiwang Wang
YLYangyi Lin
Yangyi Lin
A patient in their 40s with no medical history presented to the emergency department with chest pain of a 4-hour duration. The pain was substernal, intensified by lying supine, and relieved by leaning forward. On admission, the patient’s vital signs included a temperature of 37.3 °C, blood pressure of 147/93 mm Hg, pulse rate of 103 beats/min, and respiratory rate of 20 breaths/min. The results of the rest of the physical examination were normal. The troponin I and N-terminal pro–brain natriuretic peptide levels were normal. A transthoracic echocardiogram demonstrated normal ventricular ejection fraction, chamber size, and motion and the absence of pericardial effusion. The 12-lead electrocardiogram (ECG) at admission is shown in the Figure, A. Identify all potential conflicts of interest that might be relevant to your comment. Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued. Err on the side of full disclosure. If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response. Not all submitted comments are published. Please see our commenting policy for details.

1 April 2020 in Journal of Invasive Cardiology
Verified
Journal Article
Closed access
ZHZhiqiang Han
Zhiqiang Han
XXXiangdong Xu
Xiangdong Xu
YLYangyi Lin
Yangyi Lin
A 67-year-old man was admitted to our hospital due to chest tightness induced by activity that had started about 2 months earlier. To clarify the causes of chest pain in this patient, cardiac magnetic resonance imaging was performed, resulting in a diagnosis of ventricular apical hypertrophic cardiomyopathy with intramyocardial calcification. from Journal of Invasive Cardiology. Cardiac Imaging hypertrophic cardiomyopathy

22 July 2020 in Journal of Electrocardiology
Verified
Journal Article
Closed access
SLShu Liang
Shu Liang
GXGuolong Xu
Guolong Xu
YLYangyi Lin
Yangyi Lin